ArticleJournal of experimental & clinical cancer research : CR2026
Co-targeting CDK4/6 and MEK reverses mesenchymal transition in therapy-refractory BRAF-altered pediatric high-grade glioma.
Lisa Mayr et al.PubMed ↗Full text ↗Publisher ↗
No numbers read from the abstract.